Background: We recently reported that ATP loss by upregulated activity of AMP deaminase (AMPD)
contributes to afterload-induced diastolic dysfunction in OLETF, type 2 diabetic rats.
Here we examined the mechanism underlying the upregulation of AMPD. Methods and Results: Western blot analysis revealed that protein level of 90-kDa full-length AMPD3 was
significantly increased in the sarcoplasmic reticulum (SR) fraction (117%) as well
as in whole cell lysates (171%) in OLETF compared to its level in LETO, non-diabetic
control rats. Levels of AMPD3 mRNA determined by RT-PCR was comparable in OLETF and
LETO. Inhibitory effect of MG-132, a proteasome inhibitor, on degradation of the 90-kDa
AMPD3 ex vivo was larger in OLETF than in LETO, arguing against suppressed degradation of AMPD3
in OLETF. MicroRNA array analysis revealed downregulation (>50%) of 57 microRNAs in
OLETF compared to those in LETO. Transfection of H9c2 cells with an inhibitor of miR-301b,
one of the 57 microRNAs, significantly increased level of the 90-kDa AMPD3. Binding
of miR-301b to the 3'UTR of AMPD3 mRNA was confirmed by a luciferase reporter assay.
Conclusion: Up-regulated AMPD3 translation by reduced miR-301b mediates increased AMPD3 in the
diabetic heart. Since ATP generated by SR-associated glycolytic enzymes contributes
to Ca2+ uptake by SERCA2a and promote diastolic relaxation, AMPD3 in the vicinity of the
SR is a therapeutic target for diabetic cardiomyopathy.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Cardiac FailureAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
